Product Details
Product Name:
AZ 11645373 |
CAS No.:
227088-94-0 |
Purity:
99.47% |
Supply Ability:
10g |
Release date:
2024/11/18 |
Product Introduction
Bioactivity
名稱 | AZ 11645373 |
描述 | AZ 11645373 (3-[1-[[(3'-NITRO[1,1'-BIPHENYL]-4-YL)OXY]METHYL]-3-(4-PYRIDINYL)PROPYL]-2,4-THIAZOLIDINEDIONE) is a highly selective and potent human P2X7 receptor antagonist that has no effect on mouse/rat P2X7 receptor. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 10 mg/mL (21.57 mM)
|
關鍵字 | AZ-11645373 | AZ11645373 | AZ 11645373 |
相關產(chǎn)品 | Opiranserin hydrochloride | Aurintricarboxylic acid | (E/Z)-Sivopixant | PSB-12062 | ATP disodium salt | Oxatomide | JNJ-55308942 | JNJ-42253432 | Ivermectin | Lappaconitine | CTP disodium dihydrate | Brilliant blue G-250 |
相關庫 | 經(jīng)典已知活性庫 | 神經(jīng)信號分子庫 | 膜蛋白靶向化合物庫 | 抑制劑庫 | NO PAINS 化合物庫 | 已知活性化合物庫 | 離子通道庫 | 抗癌化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2016864-46-1
$695.00 / 10mg
-
CAS:915720-21-7
$99.00 / 1mg
-
CAS:1421373-98-9
$48.00 / 5mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$2380.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |
|
$1.00/1KG |
VIP5Y
|
Career Henan Chemica Co
|
2020-10-29 |
|
$99.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-08 |